GlioCART is a University of Basel spin-off focused on translating a dual-action CAR-T therapy for glioblastoma into clinical application by combining tumor targeting with immune microenvironment reprogramming. Our mission is to achieve durable clinical benefit for patients with glioblastoma.
Investors 1
| Date | Name | Website |
| 10.12.2025 | Venture Ki... | venturekic... |
Mentions in press and media 1
| Date | Title | Description |
| 07.07.2026 | Demo Brunch Continues to Open Doors for Switzerland's Most Promising Startups and Investors | The fourth Venture Kick Demo Brunch featured 17 Venture Kick alumni who pitched their open financing rounds to a hand-picked room of 75 qualified investors. Every founding team had already been selected multiple times by a jury of professio... |